CRCarmen Rohde

Carmen Rohde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmen Rohde has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of inadequate protein and micronutrient intakes in patients with PKU with an increased phe-tolerance: Impact of a micronutrient-dense protein substitute

    by Carmen Rohde, Denise Leonne Hofman, Ira Klawon, Frank Rutsch, Iris Rodenburg, Francjan van Spronsen, Alena Gerlinde Thiele, Willie Woestenenk, Skadi Beblo


  • Open Access

    Executive Functions and Long-Term Metabolic Control in Adults with Phenylketonuria (PKU)

    by Anne Tomm, Alena G. Thiele, Carmen Rohde, Haiko Schlögl, Wieland Kiess, Skadi Beblo

    Background/Objectives: Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by phenylalanine hydroxylase deficiency, resulting in highly elevated blood phenylalanine (Phe) concentrations, leading to neurotoxic effects. Despite advancements in treatment, adult patients with PKU may experience impairments in executive functions (EFs). This study investigates the influence of metabolic control across different life stages on EFs and sociodemographic outcomes in adult PKU. Methods: We conducted a monocentric study with 36 early-diagnosed and treated PKU patients (mean age: 34.8 years). EFs were assessed using the Test Battery for Attentional Performance (TAP) and the Tower of London (TL-D). Metabolic data were extracted from medical records, focusing on childhood and adulthood metabolic control, including Phe fluctuations. Sociodemographic data were collected via questionnaires. Statistical analyses explored relationships between EFs, metabolic control, and sociodemographic data. Results: EFs in the cohort were within the lower average range. Significant negative correlations could be observed between EF performance and dried blood Phe concentrations during childhood (ages 0–10 years) as well as current Phe concentrations and Phe variation. Elevated childhood Phe concentrations were associated with lower educational attainment. Sociodemographic characteristics, such as employment status and living arrangements, aligned with those of the general population. Conclusions: Optimal cognitive development in PKU requires good metabolic control, particularly in early childhood. In adulthood, while dietary restrictions may be relaxed, maintaining low and stable Phe concentrations is crucial for EFs. Consistent monitoring and tailored therapeutic approaches throughout life seem essential for optimizing metabolic and neurocognitive outcome in PKU.


  • Open Access

    The Prevention of Maternal Phenylketonuria (PKU) Syndrome: The Development and Evaluation of a Specific Training Program

    by Carmen Rohde, Alena Gerlinde Thiele, Anne Tomm, Dinah Lier, Kathrin Eschrich, Christoph Baerwald, Skadi Beblo

    Background: Maternal phenylketonuria (PKU) syndrome, leading to severe psychomotor retardation, microcephaly, cardiac defects and undergrowth, affects the unborn children of mothers with PKU with insufficient metabolic control during pregnancy. To improve long-term outcomes, a specific prevention program was developed. Methods: We designed a group training program for young women with PKU (>14 years) and their partners. Knowledge regarding PKU therapy and pregnancy was evaluated by a specifically developed multiple-choice questionnaire. In addition, scores of anxiety and depression were evaluated. Results: Patients (n = 20) and their partners (n = 13) significantly improved their knowledge after participation (correct answers: patients—86% vs. 90%, p = 0.003; partners—78% vs. 89%, p = 0.012). Females significantly improved their knowledge about diet (90% vs. 100%, p = 0.035) and metabolism (91% vs. 100%, p = 0.016), but not concerning gynecological topics. Patients’ median depression scores were within the normative range, with a slight decrease over time (6 points vs. 4 points, p = 0.836). Patients’ anxiety score remained stable over time (5.5 vs. 5, p = 0.247). Of trained mothers with PKU, four pregnancies with ideal metabolic control and healthy offspring could be observed. Conclusion: We suggest the inclusion of specific training programs in the standard care of female young adults with PKU, including for their partners.


  • Open Access

    Executive functions & metabolic control in phenylketonuria (PKU) and mild hyperphenylalaninemia (mHPA)

    by Anne Tomm, Alena G. Thiele, Carmen Rohde, Stefanie Kirmse, Wieland Kiess, Skadi Beblo


  • Open Access

    Preventing maternal phenylketonuria (PKU) syndrome: important factors to achieve good metabolic control throughout pregnancy

    by Carmen Rohde, Alena Gerlinde Thiele, Christoph Baerwald, Rudolf Georg Ascherl, Dinah Lier, Ulrike Och, Christina Heller, Alexandra Jung, Kathrin Schönherr, Monika Joerg-Streller, et al.

    Background: Insufficient metabolic control during pregnancy of mothers with phenylketonuria (PKU) leads to maternal PKU syndrome, a severe embryo-/fetopathy. Since maintaining or reintroducing the strict phenylalanine (Phe) limited diet in adults with PKU is challenging, we evaluated the most important dietary and psychosocial factors to gain and sustain good metabolic control in phenylketonuric women throughout pregnancy by a questionnaire survey with 38 questions concerning therapy feasibility. Among them, the key questions covered 5 essential items of PKU care as follows: General information about maternal PKU, PKU training, diet implementation, individual metabolic care, personal support. In addition, all participating PKU mothers were asked to estimate the quality of their personal metabolic control of the concluded pregnancies. 54 PKU mothers with 81 pregnancies were approached at 12 metabolic centers in Germany and Austria were included. According to metabolic control, pregnancies of PKU women were divided in two groups: group “ideal” (not more than 5% of all blood Phe concentrations during pregnancy > 360 µmol/l; n = 23) and group “suboptimal” (all others; n = 51).Results: The demand for support was equally distributed among groups, concerning both amount and content. Personal support by the direct social environment (partner, family and friends) (“suboptimal” 71% vs “ideal” 78%) as well as individual metabolic care by the specialized metabolic center (both groups around 60%) were rated as most important factors. The groups differed significantly with respect to the estimation of the quality of their metabolic situation (p < 0.001). Group “ideal” presented a 100% realistic self-assessment. In contrast, group “suboptimal” overestimated their metabolic control in 53% of the pregnancies. Offspring of group “suboptimal” showed clinical signs of maternal PKU-syndrome in 27%.Conclusion: The development of training programs by specialized metabolic centers for females with PKU in child bearing age is crucial, especially since those mothers at risk of giving birth to a child with maternal PKU syndrome are not aware of their suboptimal metabolic control. Such programs should provide specific awareness training for the own metabolic situation and should include partners and families.


  • Open Access

    Protein Substitute Requirements of Patients with Phenylketonuria on BH4 Treatment: A Systematic Review and Meta-Analysis

    by Fatma Ilgaz, Cyril Marsaux, Alex Pinto, Rani Singh, Carmen Rohde, Erdem Karabulut, Hülya Gökmen-Özel, Mirjam Kuhn, Anita MacDonald

    The traditional treatment for phenylketonuria (PKU) is a phenylalanine (Phe)-restricted diet, supplemented with a Phe-free/low-Phe protein substitute. Pharmaceutical treatment with synthetic tetrahydrobiopterin (BH4), an enzyme cofactor, allows a patient subgroup to relax their diet. However, dietary protocols guiding the adjustments of protein equivalent intake from protein substitute with BH4 treatment are lacking. We systematically reviewed protein substitute usage with long-term BH4 therapy. Electronic databases were searched for articles published between January 2000 and March 2020. Eighteen studies (306 PKU patients) were eligible. Meta-analyses demonstrated a significant increase in Phe and natural protein intakes and a significant decrease in protein equivalent intake from protein substitute with cofactor therapy. Protein substitute could be discontinued in 51% of responsive patients, but was still required in 49%, despite improvement in Phe tolerance. Normal growth was maintained, but micronutrient deficiency was observed with BH4 treatment. A systematic protocol to increase natural protein intake while reducing protein substitute dose should be followed to ensure protein and micronutrient requirements are met and sustained. We propose recommendations to guide healthcare professionals when adjusting dietary prescriptions of PKU patients on BH4. Studies investigating new therapeutic options in PKU should systematically collect data on protein substitute and natural protein intakes, as well as other nutritional factors.


  • Open Access

    Psychological well‐being of early and continuously treated phenylketonuria patients

    by Alena Gerlinde Thiele, Nicole Spieß, Rudolf Ascherl, Maria Arelin, Carmen Rohde, Wieland Kiess, Skadi Beblo

    Background Despite enormous advances in therapy, phenylketonuria (PKU) remains an incurable, inherited metabolic disease requiring life‐long treatment with potential to negatively impact quality of life and psychological well‐being. Therefore, the aim of this study was to screen early diagnosed and continuously treated children with PKU on psychological strengths and behavioral difficulties. Methods Evaluation of psychological strengths and behavioral difficulties in 49 patients with PKU (23f, 2‐17 years) by Strengths and Difficulties Questionnaire (SDQ; self‐report 11‐17 years and parent‐report 2‐17 years). Comparison to age, sex and BMI‐matched healthy controls (n = 98; 46f). Results In patients with PKU and healthy controls median SDQ Total Difficulties Score and median scores of subscales were within the normal range in parent‐ and self‐report, irrespective of sex and age group (children 2‐10 years, adolescents 11‐17 years). No influence of long‐term metabolic control in PKU on SDQ could be revealed. The 2‐ to 10‐year‐old boys with PKU showed significantly higher scores in Prosocial Behavior compared to their healthy peers (P = .032). Likewise, adolescent boys with PKU showed fewer Conduct Problems (parent‐report, P = .006). Adolescent girls with PKU rated themselves more often as abnormal in the subscale Emotional Problems compared to their healthy peers (P = .041). This subscale was also responsible for a significantly different Total SDQ Difficulties Score between patients and their parents' report (P = .008). Discussion SDQ represents a suitable instrument within the care for patients with PKU. Specific aspects, however, require separate consideration and evaluation with respect to this chronic disease. Special attention should be paid on adolescent PKU girls who seem to be at risk to develop emotional problem.


  • Open Access

    Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome

    by Friederike Bärhold, Uta Meyer, Anne-Kathrin Neugebauer, Eva Maria Thimm, Dinah Lier, Stefanie Rosenbaum-Fabian, Ulrike Och, Anna Fekete, Dorothea Möslinger, Carmen Rohde, et al.

    Background: Tyrosinaemia type 1 is a rare inherited metabolic disease caused by an enzyme defect in the tyrosine degradation pathway. It is treated using nitisinone and a low-protein diet. In a workshop in 2013, a group of nutritional specialists from Germany, Switzerland and Austria agreed to advocate a simplified low-protein diet and to allow more natural protein intake in patients with tyrosinaemia type 1. This retrospective study evaluates the recommendations made at different treatment centers and their impact on clinical symptoms and metabolic control. Methods: For this multicenter study, questionnaires were sent to nine participating treatment centers to collect data on the general therapeutic approach and data of 47 individual patients treated by those centers. Results: Dietary simplification allocating food to 3 categories led to increased tyrosine and phenylalanine blood concentrations without weighing food. Phenylalanine levels were significantly higher in comparison to a strict dietary regimen whereas tyrosine levels in plasma did not change. Non-inferiority was shown for the simplification and liberalization of the diet. Compliance with dietary recommendations was higher using the simplified diet in comparison to the stricter approach. Age correlates negatively with compliance. Conclusions: Simplification of the diet with increased natural protein intake based on three categories of food may be implemented in the diet of patients with tyrosinaemia type 1 without significantly altering metabolic control. Patient compliance is strongly influencing tyrosine blood concentrations. A subsequent prospective study with a larger sample size is necessary to get a better insight into the effect of dietary recommendations on metabolic control.


  • Ernährungstherapie bei angeborenen Erkrankungen des Aminosäurestoffwechsels

    by Carmen Rohde, Alena Thiele, Skadi Beblo

    Angeborene Stoffwechselstörungen des Aminosäurestoffwechsels zählen zur Gruppe der seltenen Erkrankungen. Abhängig vom Stoffwechseldefekt können sie unbehandelt zu schweren psychomotorischen Störungen oder zu lebensbedrohlichen metabolischen Entgleisungen führen. Mit frühzeitiger Diagnosestellung und zügigem Therapiebeginn können diagnoseabhängig die Symptome gemildert oder vollständig vermieden werden. In many cases, inborn errors of the amino acid metabolism can be treated by diet, either partial or exclusive. Phenylketonuria (PKU) is the most frequent inherited metabolic disease of the amino acid-metabolism. Untreated, PKU leads to microcephaly including severe mental retardation and strong impaired psychomotor development. PKU is detected by newborn screening. Due to an early initiation of the continuously lifelong Phe-restricted diet with supplementation of amino acids and micronutrients patients develop like healthy children. Tyrosinemia type 1 is an inborn error of tyrosine metabolism. Since April 2018 tyrosinemia type 1 is included in the German newborn screening program. Clinically patients can be noticed by growth retardation, oversize liver, tendency to bleed, soft and weak bones. Accelerated succinylacetone in urine confirms the diagnoses. Therapy consists of a pharmacological treatment with NTBC (2-(2-Nitro-4-Trifluoromethylbenzoyl)-1,3-Cyclohexanedion, Orfadin®), which helps to reduce toxic alternative metabolites. Additionally, a tyrosine restricted diet can be necessary. Urine cycle disorders can be life-threatening. Symptoms are unspecific, remind on intoxication and are easily overseen. For differential diagnosis ammonia has to be determined. Therapy is a combination of medication and diet. Protein has to be reduced to the minimum. Citrulline and arginine are able to start up the urine cycle; Na-butyrat can detox amino groups.

  • Open Access

    Early feeding practices in infants with phenylketonuria across Europe

    by A. Pinto, S. Adams, K. Ahring, H. Allen, M.F. Almeida, D. Garcia-Arenas, N. Arslan, M. Assoun, Y. Atik Altınok, D. Barrio-Carreras, et al.